温馨提示：本站仅提供公开网络链接索引服务，不存储、不篡改任何第三方内容，所有内容版权归原作者所有
AI智能索引来源：http://www.pr.com/press-release/897278
点击访问原文链接

GeneProof Announces Expansion of Its IVDR-Certified PCR Portfolio - PR.com

进入原网站 导航首页
GeneProof Announces Expansion of Its IVDR-Certified PCR Portfolio - PR.com Join Now Sign In Businesses Business Directory Products & Services Post Your Profile Press Releases Press Release Pricing Submit Press Release Press Release Distribution Recent Press Releases Become a Publishing Partner For Journalists Press Releases Businesses Products & Services Products Services Press Releases Submit Press Release ✕ Press Releases Press Release Pricing Submit Press Release Press Release Distribution Recent News Recent News News by Category News by US Region News by Country RSS News Feeds Business News Lifestyle News Public Interest News Technology News Become a Publishing Partner For Journalists Businesses Business Directory Products & Services Post Your Profile Join Now Sign In Press Release Pricing Recent News Business Lifestyle Public Interest Technology Press Release Pricing Create Account Press Release Pricing Submit Press Release Press Release Distribution Recent News Recent News News by Category News by US Region News by Country Become a Publishing Partner For Journalists RSS News Feeds Business News Lifestyle News Public Interest News Technology News Press Releases>Science>Scientific Research>ALPCO> ALPCO ALPCO Press Releases More GeneProof Announces Expansion of Its IVDR-Certified PCR Portfolio Get Email Alert RSS Brno, Czech Republic, October 03, 2023 --(PR.com)-- GeneProof, a leader in molecular diagnostics, today announced the addition of six new IVDR-certified PCR kits to its expansive portfolio. This comes as a testament to the company’s dedication to delivering its entire portfolio of approximately 80 products as IVDR compliant by 2027. Currently, 27 products are IVDR cleared, with 16 that are Notified Body certified in class C and B. These include tests for infectious diseases and immuno-compromised/transplant.

The newly added IVDR kits focus on the diagnosis of sexually transmitted infections and include:

· Multiplex CNMX: Designed for the detection of Chlamydia trachomatis, Neisseria gonorrhoeae, and Mycoplasma genitalium.

· Duplex MGH: Designed for the detection of Mycoplasma genitalium/hominis.

· Multiplex MUPX: Designed for the detection of Mycoplasma hominis, Ureaplasma urealyticum, and Ureaplasma parvum.

· Singleplex Kits: Designed for the detection of Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), and Chlamydia pneumoniae (CP), respectivly.

GeneProof was among the first to obtain the EU Certificate for Quality Management System under the new Regulation (EU) 2017/746 IVDR. The company started its IVDR compliance journey early, positioning itself as one of the first European companies to operate in full adherence with the IVDR in January of 2023.

The extensive portfolio is built on its innovative “one workflow” technology. One workflow allows combining PCR kits from different diagnostic groups (including panels for respiratory infections and vector-borne diseases) in a single run for ease-of-use and compatibility with a wide range of qPCR instruments. GeneProof also offers a specialized panel for thrombotic mutations.

Additional IVDR certified kits will be available before the end of 2023.

About ALPCO-GeneProof
ALPCO was founded in 1991 as an importer and distributor of immunoassay-based products for the North American life science markets. The company has since evolved into a leading producer of novel immunodiagnostic reagents for specialty testing laboratories. In 2022, ALPCO merged with GeneProof, a Czech Republic-based provider of specialty molecular diagnostic solutions. Founded in 2005, GeneProof offers a portfolio of approximately 80 products, 27 of which are IVDR PCR test kits for infectious diseases and genetic mutations, as well as a suite of proprietary instrumentation for clinical laboratories of all sizes. For additional information, please visit www.alpco.com and www.geneproof.com. Contact ALPCO-GeneProof
Polly Mitchell
800-592-5726
www.alpco.com Contact Categories Business Infectious Diseases Medical & Health Medical Research Science Scientific Research PR.com Press Release Distribution Submit Press Release Press Release Pricing Press Release Distribution Account Create Free Account Post Your Profile Resources Recent News RSS News Feeds For Journalists Articles Company About Contact Become a Publishing Partner Terms Privacy © 2026 PR.com and its licensors Terms Privacy Follow PR.com

智能索引记录